Background. The aim of this study was to investigate the presence of minority variants (MVs) in high-risk human papillomavirus (HPV) types (HPV-16, -52, and -58) from cervical and anal smears.
long control region, which selectively allows the amplification of A-T-rich genomes, and found the presence of G→A and C→T mutations in minority proportions in HPV-1-positive ( + ) plantar warts and HPV-16 + cervical smears [9] . APOBEC3-hypermutated variants have also been identified in the HPV-16 E2 gene using 3D-PCR [10] .
Very few studies are available on the use of ultra-deep sequencing (UDS) for whole genome analysis of HPV. UDS has been used to detect the presence of HPV minority variants (MVs) in 3 of 7 cervical HPV-16 + specimens [11] . More recently, the whole genome sequencing of a large collection of HPV-16 + case-control samples showed that the E7 gene was found to be highly conserved in cases of precancer and cancer [12] . In the same study, it was also shown that the rarely detected variants of HPV-16 have the potential to be induced by APOBEC3 mutagenic activity [12] .
However, there are few data available on the in vivo genetic diversity of hrHPV at the level of minority viral variants, and previous studies have been strictly limited to HPV-16 and cervical smears.
The aim of this study was to investigate the presence of MVs in different hrHPV types (HPV-16, -52, and -58) isolated from patients' cervical and anal samples, by performing UDS of the whole viral genome.
PATIENTS AND METHODS

Patients
Cervical or anal smears were collected during patient follow-up. Samples in which at least 1 of the hrHPV types HPV-16, -52, or -58 was detected were collected consecutively between January 2016 and March 2017 at the virology laboratory at BichatClaude Bernard Hospital in Paris, France. These samples came from consultations in the gynecology and proctology units. Samples were collected in ThinPrep liquid transport media (Hologic). This study was approved by the Research Ethics Review Committee of Robert Debré Hospital, Paris, France (number 2016/373-2).
HPV Typing
HPV DNA extraction was performed using MagNA Pure 96 DNA and Viral NA Large Volume Kit (Roche), following the manufacturer's recommendations. HPV typing was performed using the Anyplex II HPV28 kit (Seegene), which separately and semiquantitatively detects 28 HPV types: 19 high-risk (HPV types 16, 18, 26, 31, 33, 35, 39, 45 , 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 low-risk (HPV types 6, 11, 40, 42, 43, 44, 54, 61, and 70) types.
HPV Whole Genome Amplification
An 8000-bp whole genome amplification was carried out using specific primers and PrimeSTAR GXL DNA Polymerase (Clontech), a high-fidelity polymerase, to amplify long fragments. The first amplification was performed using 10 µL of the viral DNA added to 40 µL of a reaction mixture composed of 10 µL of buffer, 4 µL of dNTP, 1 µL of each primer (Table 1) , and 2 μL of PrimeSTAR GXL DNA polymerase enzyme (Clontech). The amplification program consisted of 30 cycles: 10 seconds at 98°C; 15 seconds at 55°C (HPV-16) or 60°C (HPV-52 and -58); and 90 seconds at 68°C. Then, a nested amplification was performed with the same reaction mixture conditions and similar amplification cycles. The products of amplification were assessed using 1% agarose gel electrophoresis.
HPV Whole Genome Ultra-Deep Sequencing
Libraries were prepared from purified amplification products using the Agencourt AMPure XP reagent (Beckman Coulter) and standardized to 0.2 ng/μL using Qubit Fluorometric Quantitation and Qubit dsDNA HS Assay Kit reagents HPV-16 forward  5ʹ-GCATTATATTGGTATAAAACAGG-3ʹ  5ʹ-CACGCCAGAATGGATACAAA-3ʹ   HPV-16 reverse  5ʹ-TACTACGCAATTTTGGAGGC-3ʹ  5ʹ-CAGCAATTTTTCAATTGTTTCTC-3ʹ   HPV-52 forward  5ʹ-TAGTGAGGTATATGGTACCACCC-3ʹ  5ʹ-GAATGGATAGAACAACAAACAGTATTAC-3ʹ   HPV-52 reverse  5ʹ-ATATAATGCACAGGTAGCACTTCG-3ʹ  5ʹ-GGTTCTATTACCATATGTGTTTCTGGT-3ʹ   HPV-58 forward  5ʹ-AATGTCAAATATAAGTGATGTGCAAGG-3ʹ  5ʹ-CAACACCAGAATGGATAGATAGATT-3ʹ   HPV-58 reverse  5ʹ-ATATAAGGCACATGCTTGACTTCG-3ʹ  5ʹ-TCATACATGTTTCAGGAATTGATAGTA-3ʹ Real-time Polymerase Chain Reaction of HPV-16 E2 and E6 Genes HPV-16 E2 Region HPV-16 E6 Region
Forward primer 5ʹ-AACGAAGTATCCTCTCCTGAAATTATTAG-3ʹ 5ʹ-GAGAACTGCAATGTTTCAGGACC-3ʹ
Reverse primer 5ʹ-CCAAGGCGACGGCTTTG-3ʹ 5ʹ-TGTATAGTTGTTTGCAGCTCTGTGC-3ʹ
Abbreviation: HPV, human papillomavirus.
(ThermoFisher Scientific). Each DNA sample was fragmented and bound to adapters and then indexed by 2 different indexes using the Nextera XtT DNA Library Prep kit (Illumina). Sequencing was performed using MiSeq Kit V2 reagent (300 cycles) (Illumina) on the MiSeq Illumina Sequencer. The Bowtie2 module of the Geneious software application was used to align reads and reconstruct the entire viral genome. HPV-16 reads were aligned with HPV-16 reference sequence number K02718 (GenBank). HPV-52 and HPV-58 reads were aligned with reference sequence numbers X74481 and D90400 (GenBank), respectively. The Geneious software application indicated the presence of viral variants in a minority proportion (ie, between 2% and 20%) of all reads. We required a minimal coverage of 1000× and a quality score >30. We set the detection limit for MVs at 2%. In addition, alignment of an MV at each nucleotide position was visually verified.
Phylogenetic Analyses
HPV lineage was determined using a phylogenetic tree. For each HPV type, a maximum likelihood tree was made from the global alignment of the consensus sequences and several reference sequences of each HPV lineage from GenBank [2] using RAxML software.
Assessment of APOBEC3 Editing
Bioinformatics analysis, with an "in-house" Python program, was used to determine the number of G→A and C→T mutations introduced by APOBEC3 over the whole viral genome. For each HPV-16, HPV-52, and HPV-58 genome analyzed, the ratio of the number of (G→A + C→T) / (G + C) mutations was compared to the ratio of the number of (A→G + T→C) / (A + T) mutations. We also performed a bioinformatic analysis of the nucleotide context in which these mutations occurred: TpC (thymine-phosphate-cytosine), ApC (adenine-phosphate-cytosine), CpC (cytosine-phosphate-cytosine), and GpC (guanine-phosphate-cytosine) for 5ʹ analysis and CpT (cytosine-phosphate-thymine), CpA (cytosine-phosphate-adenine), CpC (cytosine-phosphate-cytosine), and CpG (cytosine-phosphate-guanine) for 3ʹ analysis. A comparison of the expected and observed proportions of G→A and C→T mutations in each dinucleotide context allowed us to determine the preferred dinucleotide context for editing.
HPV-16 Viral Load and Percentage of Viral Genome Integration
The HPV-16 viral load was quantified using an "in-house" realtime PCR assay of HPV-16 E2 and E6 genes. The number of cells of each sample was determined by a real-time amplification of the human albumin gene as previously described by Désiré et al [13] .
The real-time quantification of HPV-16 E2 and E6 genes was adapted from a protocol previously described by Peitsaro et al [14] . The reaction medium consisted of 25 μL of TaqMan Master Mix (ThermoFisher Scientific), 1.5 μL of the forward and reverse primers, and 0.5 μL of probe ( Table 1 ). The amplification program was 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of 15 seconds at 95°C and 60 seconds at 60°C.
The percentage of viral genome integration was determined from E2 and E6 viral load values. E2 and E6 genes are present in equal amounts in the episomal form of the viral genome; however, in the case of viral genome integration, the E2 gene is deleted in almost all cases while the E6 and E7 genes are conserved. The level of viral genome integration was calculated using the following formula: [1-(E2 viral load / E6 viral load)] × 100.
Statistical Analyses
The Student or Mann-Whitney test was used to assess the relationship between the number of HPV types or stage of cytological lesions and viral diversity. The Fisher or χ 2 test was used to evaluate the relationship between HPV lineage and stage of histological lesions, to compare the number of HPV with MVs between HPV types, and to compare the number of APOBEC3 HPV-edited genomes between HPV-16 and other hrHPV types. Statistical analysis was performed using R version 3.2.4 software (http://www.R-project.org).
RESULTS
HPV Whole Genome Amplification and Ultra-Deep Sequencing
We assessed 134 routine samples (82 cervical and 52 anal [n = 26 men]) that presented at least 1 of the hrHPV types (HPV-16, -52, or -58). The samples were collected consecutively between January 2016 and March 2017 and none of the women had both cervix and anal samples. Amplification of the whole viral genome was successful in 77% of cases (n = 103/134). The rate of amplification did not vary with the presence of multiple HPV infections in the sample (P = .43), with HPV type (P = .56) or with anatomic site, although we observed a trend toward a lower amplification rate in anal than in cervical samples (67% and 83%, respectively; P = .057). UDS was successfully performed for 92 of the 103 amplified samples (89%): 55 HPV-16, 20 HPV-52, and 17 HPV-58.
Characteristics of HPV-16-Infected Patients
Patient characteristics are shown in Table 2 . HPV-16 was detected in 32 cervical and 23 anal samples. Median patient age was 34 years for cervical samples (interquartile range [IQR], 28-37 years) and 54 years for anal samples (IQR, 47-61 years). Of patients with HPV-16 for whom HIV serology was available (n = 32/55), 75% were coinfected with HIV (n = 24/32).
Anal samples were found to have a higher proportion of highgrade squamous intraepithelial lesions (HSILs) than cervical samples (56% and 19%, respectively; P = .005). Overall, multiple HPV infections were observed in 75% of samples (n = 41/55) and were more frequent in anal than in cervical samples (91% and 63%, respectively; P = .03). Multiple HPV infections were more frequent in cervical samples with low-grade squamous intraepithelial lesions (LSILs) and HSILs (n = 14/18 [77%]) than in cervical samples with atypical squamous cells of unknown significance (ASC-US) (n = 3/11 [27%]) (P = .017).
Phylogenetic analysis showed diverse HPV-16 lineages, with 39 from A lineage (71%), 3 from B lineage (5%), 9 from C lineage (17%), and 4 from D lineage (7%) (Figure 1 ).
Assessment of HPV-16 Minority Variants
Ultra-deep sequencing analysis revealed that nonsynonymous nucleotide substitutions were present in a minority proportion (ie, 2%-20%) in 20 samples (36%), with no difference between the cervical and anal samples (34% and 39%, respectively) ( Table 3 ). The median proportion of viral MVs was 3.4% (IQR, 2.2%-6.0%). In most cases (n = 12/20 [64%]), only 1 MV was present on the whole genome.
Among the viruses extracted from cervical samples, MVs were mainly located in the E1 or E2 genes (n = 21/33 [66%]), whereas for viruses from anal samples, MVs were distributed in a heterogeneous manner over the entire viral genome (P = .04 and P = .02 for E1 and E2 regions, respectively; Figure 2 ). All MVs were different, except for the R142Q substitution located in the E6 gene, which was found in 2 distinct cervical samples.
We did not find any link between the presence of MVs and cytovirological parameters such as HIV status, stage of cytological lesions, and presence of multiple infections with hrHPV and/or low-risk HPV.
APOBEC Editing of HPV-16 Sequences
Ultra-deep sequencing analysis showed footprints of APOBEC editing of HPV-16 genomes in 7 samples (13%) Analysis of the dinucleotide context of APOBEC-edited sites showed that CpG was the preferential 3′ nucleotide context, whereas TpC was the preferential 5′ nucleotide context. HPV-16 viral loads were >50 copies/cell more frequently in cases of coinfection with other hrHPV than in samples with a single HPV-16 infection (n = 15/29 [52%] vs n = 3/17 [18%], respectively; P = .03).
Median viral genome integration percentage was 58% (IQR, 35%-72%) for cervical samples and 52% (IQR, 42%-61%) for anal samples. The proportion of cervical samples with viral genome integration >50% was 36% (n = 4/11), 67% (n = 8/12), and 80% (n = 4/5) at the ASC-US, LSIL, and HSIL stages, respectively. Similarly, the proportion of anal samples with viral genome integration >50% was 33% (n = 1/3), 33% (n = 1/3), and 70% (n = 7/10) at the ASC-US, LSIL, and HSIL stages, respectively.
No association was found between the presence of MVs in cervical or anal samples and HPV-16 viral load or HPV genome integration percentage.
Analysis of HPV-52 and HPV-58 Whole Genomes
Ultra-deep sequencing was obtained in 20 HPV-52 + samples (15 cervical and 5 anal) and 17 HPV-58 + samples (12 cervical and 5 anal). Patients' characteristics are depicted in Table 2 .
Phylogenetic analysis of HPV-52 sequences showed 17 subtype A (85%) and 3 subtype B (15%). A coinfection with 2 distinct HPV-52 subtypes (A and D) was observed in 1 anal sample. Phylogenetic analysis of HPV-58 sequences showed a diversity of subtypes, with the following distribution: 6 subtype A (35%), 3 subtype B (18%), 5 subtype C (29%), and 3 subtype D (18%).
MVs were detected in 10 HPV-52 + samples (50%) and in 12 HPV-58 + samples (71%), with no difference between cervical and anal samples (Tables 4 and 5 ). The proportion of HPV MVs was higher in HPV-52/HPV-58 genomes than in HPV-16 genomes (59% vs 36%; P = .035).
In the majority of cases (80% and 92% of HPV-52 and HPV-58 genomes, respectively), there was only 1 MV along the whole viral genome.
Cervical HPV-58 + samples with an MV tended to exhibit low-risk HPV infection less frequently than those without. Indeed, coinfection with low-risk HPV was present in 12.5% (n = 1/8) of cervical HPV-58 + samples with an MV, compared to 75% (n = 3/4) of cervical HPV-58 + samples without an MV (P = .067). The same tendency was not observed for anal HPV-58 + samples or for cervical or anal HPV-52 + samples.
No HPV-58 or HPV-52 genomes were found to have been edited by APOBEC3. Thus, APOBEC3 HPV editing was observed in a higher proportion in HPV-16 genomes than in HPV-52/HPV-58 genomes (13% vs 0%; P = .04). Three HPV minority variants are located on overlapping HPV genomic regions.
Abbreviations: F, female; HPV, human papillomavirus; M, male, MV, minority variant.
cervical and 5 anal), and found the presence of at least 1 MV in 36% of HPV-16, 50% of HPV-52, and 71% of HPV-58 genomes, with no difference between anal and cervical samples. Among the cervical HPV-16 + samples, most MVs were generated by the mutagenic effect of the APOBEC3 viral restriction factor. By contrast, none of the MVs detected along the HPV-52 and HPV-58 genomes resulted from APOBEC-related mutations. Our study found that there are significant differences in patient characteristics depending on anatomic site of HPV infection. Patients with anal HPV-16 + samples were significantly more advanced in their infection than patients with cervical HPV-16 + samples; the former had (i) a higher median age (54 vs 34 years; P < .01); (ii) a higher proportion of HIV coinfection (65% vs 28%; P = .01); (iii) a greater proportion of cases of severe HSIL (56% vs 19%; P < .01); (iv) a higher proportion of multiple HPV infections (91% vs 63%; P = .03); and (v) a higher median HPV viral load (108 vs 12 copies/cell; P = .01). Although the pathophysiology of HPV infection of the anus is not yet fully understood, it could be different from that of the cervix [15] . Different indications for HPV typing could also explain the differences in patient characteristics. Thus, in France, HPV typing of cervical samples is indicated only for the ASC-US stage. By contrast, HPV typing of anal samples is recommended only for the follow-up of patients with HSIL, with especially close monitoring of HIV-infected patients.
In the present study, we observed a higher genetic diversity than that described previously [16] , with several lineages for each hrHPV. Interestingly, 16% of patients were infected with HPV-16 African C lineage, which could be explained by a large proportion of West Africa migrant patients in our center. We also found coinfections of different HPV-16 or HPV-52 lineages in 3% of patients, in similar range to the coinfections rates previously reported [17, 18] .
We evidenced HPV-16 MVs in 36% of samples, with similar proportions for anal and cervical specimens. We observed a different HPV-16 MV distribution along viral genome between cervical and anal samples, which could be linked to the possible different pathophysiology of HPV infection between the 2 sites. In the majority of cases, only 1 nonsilent MV was observed per viral genome, highlighting the low rate of error with DNA viruses, as expected. We did not find an association between the presence of HPV-16 MVs and cytovirological variables (ie, stage of cytological lesions, viral load, and percentage of viral genome integration). This could result from a lack of power in statistical analyses. Furthermore, studies evaluating the association between viral load, stage of cytological lesions, and prognosis of infection have shown contradictory results; however, different amplification techniques, standards, and normalization protocols were used [19, 20] . Regarding the other hrHPVs assessed in our study, the proportion of samples exhibiting MVs was higher for HPV-58 + and HPV-52 + samples than for HPV-16 + (P = .035). In our study, 13% of HPV genomes from anal and cervical samples were found to have been edited by APOBEC3 cellular proteins. These data are fairly similar to previous findings on HPV genomes in plantar warts (17%) and cervical swabs (22%) [9] . We also showed that the preferential dinucleotide context for editing of the major cytidine was TpC at 5ʹ, which is known to favor the editing activity of APOBEC3A and 3C and 3H cellular proteins. These proteins are present in the epithelial cells of cervical and anal mucosa [21] . Vartanian et al also found a preferential 5ʹ dinucleotide context in favor of TpC, and, to a lesser extent, CpC [9] . APOBEC cellular proteins have also been found to be involved in the generation of somatic mutations in host genomes that could contribute to cancer progression [22] . Furthermore, HPV-positive head and neck cancer genomes contain high levels of APOBEC3-mediated mutations, whereas HPV-negative head and neck cancer genomes exhibit a smoking-associated mutational signature [23, 24] . It has been shown that APOBEC3 expression is significantly elevated by the HPV oncoproteins E6 and E7 during persistent viral infection and disease progression [7] . Interestingly, in our study, 55% of MVs present in HPV-16 viral genomes were APOBEC3-related mutations. By contrast, none of the MVs detected in HPV-52 and HPV-58 viral genomes resulted from APOBEC3 editing. All 3 HPV types assessed in our study are hrHPV, but HPV-16 exhibited the highest risk of cancer progression. Thus, with APOBEC3 mutations being found only in HPV-16 in our study, we can hypothesize that the mutagenic activity of APOBEC3 could participate in the multifactorial oncogenic process.
Our study has several limitations, including the consecutive selection of patients based only on HPV type, the small number of patients with HPV-52 and HPV-58, and the small number of cervical samples at advanced cytological stages. In addition, we have no data regarding the number of sexual partners and the presence of other sexually transmitted infections.
We report, for the first time, the presence of hrHPV MVs in anal samples. Overall, about half of both cervical and anal samples assessed exhibited 1 MV along the hrHPV genome. Interestingly, we also observed a differential impact of APOBEC3 mutagenic activity depending on hrHPV type, suggesting that it could play a potential role in carcinogenesis. Further experiments are needed to understand the impact of this low-level variability. Further studies are especially needed to assess viral genetic variability in longitudinal samples from the same patient at different histological stages.
